Similar articles for PMID: 19423567

Year	Number of Results
1997	1
2002	1
2004	1
2006	1
2007	4
2008	5
2009	10
2010	11
2011	8
2012	15
2013	9
2014	3
2015	2
2016	4
2017	5
2018	3
2019	8
2020	4
2021	0

1

Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality.

Boudville NC, Djurdjev O, Macdougall IC, de Francisco AL, Deray G, Besarab A, Stevens PE, Walker RG, Ureña P, Iñigo P, Minutolo R, Haviv YS, Yeates K, Agüera ML, MacRae JM, Levin A. Boudville NC, et al. Clin J Am Soc Nephrol. 2009 Jul;4(7):1176-82. doi: 10.2215/CJN.04920908. Epub 2009 May 7. Clin J Am Soc Nephrol. 2009. PMID: 19423567 Free PMC article.

2

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T. Tsubakihara Y, et al. Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x. Ther Apher Dial. 2010. PMID: 20609178

3

Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.

Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, Mascia S, Laurino S, Bertino V, Conte G, De Nicola L. Minutolo R, et al. Clin J Am Soc Nephrol. 2009 Mar;4(3):552-9. doi: 10.2215/CJN.04380808. Epub 2009 Mar 4. Clin J Am Soc Nephrol. 2009. PMID: 19261821 Free PMC article.

4

Hemoglobin level variability in renal transplant patients treated with erythropoiesis stimulating agents.

Fernández Fresnedo G, de Francisco AL, Ruiz JC, Gómez Alamillo C, Arias M. Fernández Fresnedo G, et al. Transplant Proc. 2008 Nov;40(9):2919-21. doi: 10.1016/j.transproceed.2008.08.093. Transplant Proc. 2008. PMID: 19010147

5

[Regarding the optimal hemoglobin target range in renal anemia].

Maurin N. Maurin N. Med Klin (Munich). 2008 Sep 15;103(9):633-7. doi: 10.1007/s00063-008-1102-3. Epub 2008 Sep 24. Med Klin (Munich). 2008. PMID: 18813886 Review. German.

6

Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.

Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM. Maddux FW, et al. Ann Pharmacother. 2007 Nov;41(11):1761-9. doi: 10.1345/aph.1K194. Epub 2007 Sep 25. Ann Pharmacother. 2007. PMID: 17895328

7

Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.

Kiss Z, Ambrus C, Almasi C, Berta K, Deak G, Horonyi P, Kiss I, Lakatos P, Marton A, Molnar MZ, Nemeth Z, Szabo A, Mucsi I. Kiss Z, et al. Nephron Clin Pract. 2011;117(4):c373-8. doi: 10.1159/000321521. Epub 2010 Nov 12. Nephron Clin Pract. 2011. PMID: 21071961

8

Hemoglobin variability does not predict mortality in European hemodialysis patients.

Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E, Fouqueray B, Macdougall IC. Eckardt KU, et al. J Am Soc Nephrol. 2010 Oct;21(10):1765-75. doi: 10.1681/ASN.2009101017. Epub 2010 Aug 26. J Am Soc Nephrol. 2010. PMID: 20798262 Free PMC article.

9

Transfusion burden among patients with chronic kidney disease and anemia.

Lawler EV, Bradbury BD, Fonda JR, Gaziano JM, Gagnon DR. Lawler EV, et al. Clin J Am Soc Nephrol. 2010 Apr;5(4):667-72. doi: 10.2215/CJN.06020809. Epub 2010 Mar 18. Clin J Am Soc Nephrol. 2010. PMID: 20299366 Free PMC article.

10

Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents.

Farag YM, Keithy-Reddy SR, Mittal BV, Bansal V, Fareed J, Singh AK. Farag YM, et al. Clin Appl Thromb Hemost. 2012 Sep;18(5):453-61. doi: 10.1177/1076029611431954. Epub 2012 Apr 11. Clin Appl Thromb Hemost. 2012. PMID: 22496088 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed